LSD1 as a Biomarker and the Outcome of Its Inhibitors in the Clinical Trial: The Therapy Opportunity in Tumor

Figure 1

LSD1 interacting partners and functional diversity [18]. LSD1 contains several protein complexes (such as “NuRD and RCOR2”), receptors (such as “estrogen and androgen”), noncoding RNAs (such as “HOTAIR and SRA”), microRNAs (such as “miR-137 and miR-329”), non-histone proteins (such as “p53 and E2F1”), and transcription factors (such as “TLA and SNAIL”). The reaction of LSD1 among varied factors permits the varied directive of diverse biological procedures via the suppression and the activation of target gene expression subject on the mode of its interrelating partners; thus, LSD1 is downregulated when there is the reaction of LSD1 with miR-137 and results in cell differentiation by activating the linked genes. When associated with CoREST, it results in downregulation of LSD1 and suppresses target genes.